De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Medifast Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Medifast zullen naar verwachting dalen met respectievelijk 20.1% en 79.9% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 80.5% per jaar.

Belangrijke informatie

-79.9%

Groei van de winst

-80.5%

Groei van de winst per aandeel

Personal Products winstgroei	23.8%
Inkomstengroei	-20.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	06 Aug 2024

Recente toekomstige groei-updates

Recent updates

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

Sep 03

Medifast Business Continues To Shrink, Stock Still Risky

Aug 27

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Jun 26

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19

Medifast declares $1.64 dividend

Dec 08

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Dec 01

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 10

One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Nov 08

Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy

Nov 06

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Oct 20

We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Sep 18

Medifast declares $1.64 dividend

Sep 08

Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Sep 02

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Aug 21

Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Aug 09

Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

Jul 27

Winst- en omzetgroeiprognoses

NYSE:MED - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	556	7	24	30	2
12/31/2024	607	-5	21	32	2
6/30/2024	770	29	54	61	N/A
3/31/2024	898	68	85	91	N/A
12/31/2023	1,072	99	141	148	N/A
9/30/2023	1,218	120	174	189	N/A
6/30/2023	1,373	133	200	214	N/A
3/31/2023	1,530	142	199	215	N/A
12/31/2022	1,599	144	178	195	N/A
9/30/2022	1,639	151	116	135	N/A
6/30/2022	1,662	157	68	96	N/A
3/31/2022	1,603	165	40	73	N/A
12/31/2021	1,526	164	60	95	N/A
9/30/2021	1,413	158	97	122	N/A
6/30/2021	1,271	150	130	147	N/A
3/31/2021	1,097	125	174	184	N/A
12/31/2020	935	103	139	145	N/A
9/30/2020	841	95	140	145	N/A
6/30/2020	759	76	118	121	N/A
3/31/2020	726	76	72	78	N/A
12/31/2019	714	78	74	84	N/A
9/30/2019	689	74	70	80	N/A
6/30/2019	638	72	60	69	N/A
3/31/2019	568	64	67	76	N/A
12/31/2018	501	56	56	61	N/A
9/30/2018	433	47	51	55	N/A
6/30/2018	371	40	57	61	N/A
3/31/2018	330	34	N/A	55	N/A
12/31/2017	302	28	N/A	43	N/A
9/30/2017	286	25	N/A	33	N/A
6/30/2017	277	24	N/A	27	N/A
3/31/2017	273	20	N/A	24	N/A
12/31/2016	275	18	N/A	25	N/A
9/30/2016	273	18	N/A	28	N/A
6/30/2016	271	17	N/A	30	N/A
3/31/2016	272	19	N/A	27	N/A
12/31/2015	273	20	N/A	29	N/A
9/30/2015	274	18	N/A	28	N/A
6/30/2015	277	18	N/A	27	N/A
3/31/2015	279	19	N/A	25	N/A
12/31/2014	285	21	N/A	26	N/A
9/30/2014	267	27	N/A	33	N/A
6/30/2014	285	27	N/A	31	N/A
3/31/2014	307	28	N/A	38	N/A
12/31/2013	324	27	N/A	42	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van MED zal naar verwachting de komende 3 jaar dalen ( -79.9% per jaar).

Winst versus markt: De winst van MED zal naar verwachting de komende 3 jaar dalen ( -79.9% per jaar).

Hoge groeiwinsten: De winst van MED zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van MED zal naar verwachting de komende 3 jaar dalen ( -20.1% per jaar).

Hoge groei-inkomsten: De omzet van MED zal naar verwachting de komende 3 jaar dalen ( -20.1% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MED naar verwachting over 3 jaar hoog zal zijn

Medifast Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 15% to US$21.25

Consensus EPS estimates fall by 54%

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Consensus revenue estimates fall by 15%

Medifast Provides Earnings Guidance for the First Quarter of 2024

Price target decreased by 14% to US$62.50

Recent updates

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

Medifast Business Continues To Shrink, Stock Still Risky

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 15% to US$21.25

Medifast: Significant Undervaluation Even As Struggles Persist

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

Investor sentiment deteriorates as stock falls 25%

Consensus EPS estimates fall by 54%

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

First quarter 2024 earnings: EPS misses analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Medifast: Cheap Valuation, Uncertain Future

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Medifast Is Getting Attractive

Investor sentiment deteriorates as stock falls 17%

Consensus revenue estimates fall by 15%

New major risk - Revenue and earnings growth

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2023 earnings: EPS misses analyst expectations

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Price target decreased by 14% to US$62.50

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Investor sentiment deteriorates as stock falls 16%

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Consensus EPS estimates increase by 11%, revenue downgraded

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Now 21% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Insider selling

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Lead Independent Director notifies of intention to sell stock

Price target decreased by 14% to US$80.00

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Price target increased by 31% to US$93.00

Medifast Unveils New Product Line, Optavia Active

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Now 20% undervalued after recent price drop

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast: In Survival Mode Against Diet Pills And The Recession

Medifast Holds Value During Headwinds

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Consensus EPS estimates fall by 25%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Full year 2022 earnings: EPS exceeds analyst expectations

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?